Enhancement of the Antiparakeratotic Potency of Calcitriol and Tacalcitol in Liposomal Preparations in the Mouse Tail Test

In order to test the advantage of vitamin D3 preparations in liposomal form, calcitriol, the natural activated form of vitamin D3, and tacalcitol, a vitamin D3 analogue, were employed in various concentrations and using different vehicles in the mouse tail test, an animal model for testing the antiparakeratotic efficacy of topical medications. The optimal concentration in petrolatum turned out to be similar to that in commercial preparations. The liposomal preparations were superior to those in petrolatum and to those in nonliposomal phospholipids. The antiparakeratotic potency (drug activity) of liposomal tacalcitol in a concentration of 2 µg/g was twice that of the commercial preparation with a higher concentration of 4 µg/g. These results suggest that the use of liposomal vitamin D3 preparations can achieve a given antipsoriatic effect with a reduced concentration of the active substance thereby reducing the risk of skin irritation and of hypercalcemia.

[1]  B. Bonnekoh,et al.  Tazarotene Induces Epidermal Cell Differentiation in the Mouse Tail Test Used as an Animal Model for Psoriasis , 2000, Skin Pharmacology and Physiology.

[2]  M. Holick,et al.  A Liposomal Model That Mimics the Cutaneous Production of Vitamin D3 , 1999, The Journal of Biological Chemistry.

[3]  P. Kerkhof.  Reduction of epidermal abnormalities and inflammatory changes in psoriatic plaques during treatment with vitamin D3 analogs. , 1996 .

[4]  P. Kerkhof,et al.  Transglutaminase‐positive cells in psoriatic epidermis during treatment with calcitriol (1α, 25 dihydroxy vitamin D3) and tacalcitol (1α, 24 dihydroxy vitamin D3) , 1995, The British journal of dermatology.

[5]  P. Kerkhof.  Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms , 1995 .

[6]  I. Vlijmen-Willems,et al.  The effect of tacalcitol (1,24(OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo‐controlled, double‐blind study , 1994 .

[7]  J. Bourke,et al.  Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris , 1993, Clinical and experimental dermatology.

[8]  N. Weiner,et al.  Topical delivery of liposomally encapsulated gamma-interferon. , 1992, Antiviral research.

[9]  H. Korting,et al.  Topical liposome drugs to come: what the patent literature tells us. A review. , 1991, Journal of the American Academy of Dermatology.

[10]  M. Darmon,et al.  1,25-Dihydroxyvitamin D3 stimulates specifically the last steps of epidermal differentiation of cultured human keratinocytes. , 1991, Differentiation; research in biological diversity.

[11]  B. Bonnekoh,et al.  Increase of lipid fluidity and suppression of proliferation resulting from liposome uptake by human keratinocytes in vitro , 1991, The British journal of dermatology.

[12]  P. Kerkhof.  An Update on Vitamin D3 Analogues in the Treatment of Psoriasis , 1998 .

[13]  J. Reichrath,et al.  Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. , 1997, Journal of the American Academy of Dermatology.

[14]  T. Szabados,et al.  Effect of fumaric acid, its dimethylester, and topical antipsoriatic drugs on epidermal differentiation in the mouse tail model. , 1996, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[15]  J. Fluhr,et al.  Therapeutischer Nutzen von Tacalcitol bei der Psoriasis vulgaris unter besonderer Berücksichtigung der okklusiven Applikation , 1996 .

[16]  P. C. van de Kerkhof.  Reduction of epidermal abnormalities and inflammatory changes in psoriatic plaques during treatment with vitamin D3 analogs. , 1996, The journal of investigative dermatology. Symposium proceedings.

[17]  P. C. van de Kerkhof.  Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. , 1995, The British journal of dermatology.

[18]  B. Sternberg,et al.  Incorporation of vitamin D3-derivatives in liposomes of different lipid types. , 1994, Journal of drug targeting.

[19]  B. Bosman.  Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis. , 1994, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[20]  H. Korting,et al.  Liposomes: a drug carrier system for topical treatment in dermatology. , 1994, Critical reviews in therapeutic drug carrier systems.

[21]  B. Sternberg,et al.  Interaction of liposomal incorporated vitamin D3-analogues and human keratinocytes. , 1994, Journal of drug targeting.

[22]  Korting Hc,et al.  Liposomes: a drug carrier system for topical treatment in dermatology. , 1994 .

[23]  F. Bonte,et al.  Cutaneous bioavailability in hairless rats of tretinoin in liposomes or gel. , 1993, Journal of pharmaceutical sciences.

[24]  T. Matthiesen,et al.  A quantitative method for measuring antipsoriatic activity of drugs by the mouse tail test. , 1992, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[25]  R. Thieroff-Ekerdt,et al.  Effects of calcipotriol (MC 903) and calcitriol after topical application on the skin of hairless rats. Much lower effect of calcipotriol on systemic calcium homeostasis. , 1992, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[26]  B. Bonnekoh,et al.  [Cutaneous administration of liposomes--a review of the literature with special reference to findings from keratinocyte cultures, animal experiments and clinical studies]. , 1990, Zeitschrift fur Hautkrankheiten.

[27]  W. Wohlrab,et al.  The effect of liposomal incorporation of topically applied hydrocortisone on its serum concentration and urinary excretion. , 1989, Dermatologische Monatschrift.

[28]  A Liposomal Model That Mimics the Cutaneous Production of Vitamin D 3 STUDIES OF THE MECHANISM OF THE MEMBRANE-ENHANCED THERMAL ISOMERIZATION OF PREVITAMIN D 3 TO VITAMIN D 3 * , 2022 .